NUFORMIX PLC

Capital/Financing Update • May 24, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1024A

Nuformix PLC

24 May 2019

Nuformix plc

("Nuformix" or the "Company")

Conversion of Loan Note

Cambridge, UK, 16 May 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has received notice from Mr Alan Miller in accordance with the Convertible Loan Agreement dated 18 April 2017 (as amended) to convert the outstanding loan of £200,000 with accrued interest ("Loan"). In accordance with the notice the Company has today issued 8,716,512 ordinary shares fully paid and 8,716,512 warrants to subscribe for ordinary shares at 2.75p per share exercisable at any time for 60 months to Mr Miller in settlement of the Loan.

Enquiries:

Nuformix plc Dr Dan Gooding, Chief Executive Officer Tel: +44 (0)1223 423667

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CONFMGZKKDMGLZG